AstraZeneca (LON:AZN) drug Farxiga successfully negotiated a large phase III trial of people with type-2 diabetes.
DECLARE-TIMI 58 involved 17,000 patients with the disease. The AZ treatment had a statistically significant impact on hospitalisation for heart failure and cardiovascular death in the group studied.
“The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden,” said Elisabeth Björk, head of AZ’s cardiovascular operation.